Muscle Pharm Corp. provided earnings guidance for the fourth quarter and full year ended December 31, 2011. On a preliminary basis, the company expected gross revenues for the quarter ended December 31, 2011 of approximately $8,000,000 an increase of 830% as compared to gross revenues of approximately $860,000 during the corresponding quarter ended December 31, 2010. The company expected to report a net operating loss and a loss associated with convertible financing derivatives for the quarter ended December 31, 2011. The company's sales for the year 2011 are expected to be approximately $21,000,000, which is an increase of 425%, compared to $4,000,000 reported in 2010.